Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Evaluation of Kinerase Pro+Therapy Regimen Vs. Kinerase Vs. Control for the Treatment of Skin Aging

This study has been terminated.
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT00492479
First received: June 25, 2007
Last updated: December 18, 2007
Last verified: December 2007
  Purpose

The purpose of this study is to compare the efficacy of the Kinerase Pro+Therapy regimen versus a single Kinerase product vs. control for the treatment of the signs of skin aging.


Condition Intervention Phase
Skin Aging
Drug: Kinerase Pro+Therapy Line day repair, serum, night repair
Drug: Kinerase Pro+Therapy Line Ultra rich day repair
Drug: LubriDerm
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind

Resource links provided by NLM:


Further study details as provided by Innovative Medical:

Study Start Date: June 2007
Study Completion Date: December 2007
  Eligibility

Ages Eligible for Study:   35 Years to 55 Years
Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Female patients 35-55 years of age with at least moderate signs of facial aging
  • Written informed consent
  • Likely to complete all study visits and follow study protocol

Exclusion Criteria:

  • Any dermatological or medical condition which would make patient participation unsafe or interfere with study outcomes or measurements
  • Known hypersensitivity to any study product or their components
  • Recent (within 4 weeks of baseline) surgical treatment to face (including IPL and other laser procedures)
  • Prior use of anti-aging treatments for 30 days prior to study entry (physician dispensed or prescribed treatments)
  • Planned facial procedures during the study (microdermabrasion, facials, etc)

    o Botox and fillers cannot be used during the trial or for 3 months prior to study entry

  • Recent (within 60 days) or concurrent participation in another clinical trial
  • Concomitant topical or systemic therapy that my interfere with study measurements or outcomes
  • Use of any other topical photoaging/antiaging therapies during the study, other than the prescribed study regimens
  • Patients who are habitual tanners (outdoors or with tanning beds) who plan on tanning during the study
  • Wearing of cosmetics during study visits
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00492479

Locations
United States, California
Steve Yoelin MD practice
Santa Ana, California, United States, 92701
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Steven Yoelin, MD Private Practice
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00492479     History of Changes
Other Study ID Numbers: 5314
Study First Received: June 25, 2007
Last Updated: December 18, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Kinetin
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Plant Growth Regulators

ClinicalTrials.gov processed this record on November 25, 2014